KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $223.5 million.

  • Alnylam Pharmaceuticals' Change in Accured Expenses rose 16737.13% to $223.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $187.8 million, marking a year-over-year increase of 6398.01%. This contributed to the annual value of $91.1 million for FY2024, which is 1268.31% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Change in Accured Expenses stood at $223.5 million, which was up 16737.13% from $182.1 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Change in Accured Expenses ranged from a high of $223.5 million in Q3 2025 and a low of -$155.7 million during Q1 2025
  • In the last 5 years, Alnylam Pharmaceuticals' Change in Accured Expenses had a median value of $68.1 million in 2022 and averaged $36.9 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Change in Accured Expenses soared by 32426.31% in 2021, and later plummeted by 310117.16% in 2025.
  • Alnylam Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $39.5 million in 2021, then soared by 159.78% to $102.6 million in 2022, then crashed by 137.68% to -$38.7 million in 2023, then plummeted by 60.62% to -$62.1 million in 2024, then soared by 459.88% to $223.5 million in 2025.
  • Its last three reported values are $223.5 million in Q3 2025, $182.1 million for Q2 2025, and -$155.7 million during Q1 2025.